BrainChild Bio
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Biopharma, Cell therapy, Oncology
- Stage
- Series A
- Founders
- Michael Jensen, MD
Jacob Colker announces Seattle startups score major wins: Stoke Space $1B raise, BrainChild Bio $116M, Nuance Labs $50M, Helion expands
A roundup by Jacob Colker highlights major Seattle-area tech and biotech funding and growth: Stoke Space raised $1B (now $2.3B) for reusable rockets, BrainChild Bio $116M for a CAR-T DIPG trial, General Robotics offers rapid robot deployment, Helion expands amid fusion commercialization with 800+ employees, and Nuance Labs raised $50M for multimodal AI.
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
People
-
Michael Jensen Founder, Founder and Chief Scientific Officer
-
Steven Brugger Executive, CEO
